Bacil Pharma reports zero revenue for FY26
The nano-cap firm remains non-operational, relying on investment income to fund a loss of ₹61.88 lakhs.
— 9 earlier stories on Bacil Pharma Ltd. →What's new
- Bacil Pharma posted zero operating revenue for FY26.
- The firm recorded ₹123.52 lakhs in income from investments.
- Auditors issued an unmodified opinion with an emphasis of matter.
Why this matters
The annual report confirms the firm has no commercial business. It relies entirely on asset returns to survive. The results offer no evidence of a path forward.
What we're watching
- Any potential pivot in business strategy.
- Updates regarding the company's long-standing governance issues.
- Changes to the investment portfolio.
The full read
Bacil Pharma’s FY26 results confirm the firm is an inactive shell. The company reported zero operating revenue for the year, relying entirely on ₹123.52 lakhs in other income derived from its investments. After accounting for fair value losses on financial assets, the company booked a total loss of ₹61.88 lakhs.
Auditors provided an unmodified opinion, though they added an emphasis of matter paragraph. These figures surprise no one. They align with previous quarterly disclosures detailing the company’s lack of commercial operations. This filing is a routine regulatory requirement that signals the firm’s continued stagnation. With no pending litigation reported, the business remains stuck in a holding pattern.
Nothing changed.
Questions answered
- Did the company generate any revenue in FY26?
- No. Bacil Pharma reported zero operating revenue for the financial year ending March 31, 2026.
- What drove the company's loss this year?
- The loss of ₹61.88 lakhs stemmed from fair value losses on its financial assets.
Bacil Pharma Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on BACPHAR →- 22 May 2026 · 8:46 PM IST Bacil Pharma reports zero revenue for FY26
- today Bacil Pharma plans ₹50 cr rights issue — equal to its entire market cap
- 11d ago Mumbai investor Niraj Shah buys 6.44% stake in zero-revenue Bacil Pharma
- 15d ago Bacil Pharma loses another large holder as Shah sells 2.75% stake
- 16d ago Bacil Pharma loses another big holder — Patel cuts stake by 7.10%